This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Factor V Leiden mutation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Resistance to the anticoagulant effects of activated protein C (APC) (Factor V Leiden heterozygous*) is common (1):

  • 5% of the general population
  • 25-50% of patients with venous thromboembolism
  • 50% of patients with thrombosis who have a family or personal history of thrombosis

APC resistance is usually due to a single point mutation in one or both of the protein C genes. The mutation reduces the susceptibility of factor V to cleavage by APC.

There is increasing evidence that individuals with two or more laboratory characterisable thrombophilic abnormalities (or who are homozygous for either factor V Leiden or prothrombin G20210A) are at a greater risk of thrombosis than those in whom there is a single gene abnormality (1).

* Factor V Leiden homozygous individuals have an 80x risk of venous thromboembolism

Reference:

(1) British Heart Foundation (Factfile 2/2002). Thrombophilia

(2) Rogier, MB. et al. (1994). Mutation in blood coaulation factor V associated with resistance to activated protein C. Nature, 369, 64-7.

(3) Drugs and Therapeutics Bulletin (1995), 33 (1), 6-8.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.